Interview with Zheng Hong, Chairman, China Pharmaceutical Industry Association…
You have a very long history in the Chinese pharmaceutical industry, first in the joint venture company…
China Pharmaceutical Industry Association (CPIA)
Last updated: 13.02.2014
Address: No. 20, Zhichun Rd., Haidian District, Beijing,China
Tel: -82080673
Company description
China Pharmaceutical Industry Association (CPIA) was founded in September 1988 and it is a non-governmental, non-profit association, Its members are mainly from large and medium sized pharmaceutical corporations, pharmaceutical machinery and medicinal glass packaging companies, regional pharmaceutical industrial associations, pharmaceutical research institutions, designing institutes, universities, colleges and secondary schools of this sector etc. CPIA is a national level society registered in the Ministry of Civil Affairs. The State-owned Assets Supervision and Administration Commission of the State Council directly administer the association. CPIA is a member and also a standing council director’s unit of China Federation of Industrial Economics.
Now CPIA has 338 members, the industrial output value of which (added together) is nearly up to 80 percent of that of the whole China’s pharmaceutical industry. CPIA also has 15 professional working units: 2 branch associations, 13 working & coordinating committees and communication groups.
Products and services
Industry association
Interviews
Related
China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
China / Public Insurance Coverage for Rare Disease Patients: Beijing & Shanghai Surprisingly Low in New City Ranking
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
China / AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan for Pharmaron; Clover’s $230 Million Investment Boost
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
China / Yangtze River Pharmaceutical Group (YRPG) in Profile
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
China / HiFiBiO CEO on the Keys to Global Biotech Success
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
China / New Drug Approvals 2020
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Liang Schweizer – CEO & CSO, HiFiBiO Therapeutics
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
China / National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
China / New Year, New Round of Drug Price Cuts
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
China / 5 Top Trends in Healthcare & Biopharma in 2020
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
Global / 2020's Top 7 Biotech IPOs In Profile
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of…
